Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2009-03-01

Summary

This is a phase 2 study that will consist of 4 visits over a 5 week period. Drug will be evaluated using the conjunctival allergen challenge model of allergic conjunctivitis.

• Phase: Phase 2

Details

• Lead Sponsor: Senju USA, Inc.
• Treatments: Ketotifen; Lubricant Eye Drops; Olopatadine Hydrochloride; Ophthalmic Solutions